By Fineline Cube 
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8 million) via a Pre-Series A financing round. Led by Growth FoF, the funding included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group, Henry WU, and Shanghai Healthcare Capital, among others. The proceeds will be used to bolster the clinical development of its heart gene therapy core pipeline, JV101, including expansion studies for heart failure.
JV101: Innovative Heart Gene Therapy
JV101, Juvensis Therapeutics’ lead program, was filed for clinical trials in China late last year. The therapy has demonstrated preliminary safety and efficacy in an Investigator-Initiated Trial (ITT), showing promise in addressing the significant unmet needs in heart failure treatment. The funding will support further clinical trials to evaluate its potential to improve cardiac function and patient outcomes.
Technology Platform and Future Outlook
Juvensis Therapeutics utilizes a next-generation telomere precise regulation technology platform to develop gene therapies against cardiovascular, neurological, and renal diseases from the perspective of aging. This innovative approach positions the company at the forefront of anti-aging research, with JV101 representing a potential breakthrough in the treatment of age-related conditions.-Fineline Info & Tech